| Outcome Measures: |
Primary: The proportion of patients with clinically important GI bleeding, 90 days or length of ICU stay, as applicable | Secondary: Proportion of patients with one or more of the following adverse events: clinically important GI bleeding, pneumonia, C. difficile infection, or acute myocardial ischemia in the ICU, 90 days or length of ICU stay, as applicable|Proportion of patients with serious adverse reactions, 90 days or length of ICU stay, as applicable|Proportion of patients with one or more infectious adverse events (pneumonia or CDI) in the ICU, 90 days or length of ICU stay, as applicable|Days alive without use of mechanical ventilation, renal replacement therapy, or circulatory support in the 90-day period, 90 days or length of ICU stay, as applicable|90-day and 1-year (365 days) mortality post-randomization, 90 days/365 days or length of ICU stay, as applicable|Proportion of patients receiving treatment (interventions) to stop GI-bleeding (i.e. endoscopy/ open or laparoscopic surgery/ coiling)., 90 days or length of ICU stay, as applicable|Number of units of packed red blood cells (RBCs) transfused., 90 days or length of ICU stay, as applicable|90-day/360-day/ ICU mortality rate in "RRT group" vs. "ESRD group" vs. "RRT at any time on the ICU" vs. "control group" incl. analysis of verum/ placebo subgroups., 90 day, 360 days, or length of ICU stay, as applicable
|
| Locations: |
Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care Medicine, University of Bern,, Bern, 3010, Switzerland
|
